OncoMatch/Clinical Trials/NCT06714383

Trilaciclib Combing Chemotherapy in the Neoadjuvant Treatment of Osteosarcoma

Is NCT06714383 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Trilaciclib and Pirarubicin for osteosarcoma.

Phase 2RecruitingPeking University People's HospitalNCT06714383Data as of May 2026

Treatment: Trilaciclib · Pirarubicin · Lobaplatin — To evaluate the clinical application value in bone marrow protection of Trilaciclib in the neoadjuvant treatment of stage II/III classic osteosarcoma in combination with pirarubicin and lobaplatin.

Check if I qualify

Extracted eligibility criteria

Cancer type

Osteosarcoma

Disease stage

Required: Stage Ⅱ, Ⅲ (Enneking)

Grade: high grade

Newly diagnosed stage Ⅱ-Ⅲ based on Enneking staging criteria

Performance status

ECOG 0–1(Restricted strenuous activity)

Prior therapy

No prior treatment (treatment-naive required)

Max 0 prior lines

Lab requirements

Blood counts

Kidney function

Liver function

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify